JP2013518057A - 芳香族カチオン性ペプチドおよびその使用 - Google Patents

芳香族カチオン性ペプチドおよびその使用 Download PDF

Info

Publication number
JP2013518057A
JP2013518057A JP2012550189A JP2012550189A JP2013518057A JP 2013518057 A JP2013518057 A JP 2013518057A JP 2012550189 A JP2012550189 A JP 2012550189A JP 2012550189 A JP2012550189 A JP 2012550189A JP 2013518057 A JP2013518057 A JP 2013518057A
Authority
JP
Japan
Prior art keywords
lys
dmt
arg
peptide
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012550189A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013518057A5 (enExample
Inventor
ヘイゼル エイチ セトー
ピーター ダブリュー シラー
Original Assignee
コーネル ユニヴァーシティー
アンスティテュ ド ルシェルシュ クリニーク ド モントリオール
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーネル ユニヴァーシティー, アンスティテュ ド ルシェルシュ クリニーク ド モントリオール filed Critical コーネル ユニヴァーシティー
Publication of JP2013518057A publication Critical patent/JP2013518057A/ja
Publication of JP2013518057A5 publication Critical patent/JP2013518057A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2012550189A 2010-01-25 2011-01-24 芳香族カチオン性ペプチドおよびその使用 Pending JP2013518057A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29806210P 2010-01-25 2010-01-25
US61/298,062 2010-01-25
PCT/US2011/022247 WO2011091357A1 (en) 2010-01-25 2011-01-24 Aromatic-cationic peptides and uses of same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015163826A Division JP2016000750A (ja) 2010-01-25 2015-08-21 芳香族カチオン性ペプチドおよびその使用

Publications (2)

Publication Number Publication Date
JP2013518057A true JP2013518057A (ja) 2013-05-20
JP2013518057A5 JP2013518057A5 (enExample) 2014-03-13

Family

ID=44307257

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012550189A Pending JP2013518057A (ja) 2010-01-25 2011-01-24 芳香族カチオン性ペプチドおよびその使用
JP2015163826A Pending JP2016000750A (ja) 2010-01-25 2015-08-21 芳香族カチオン性ペプチドおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015163826A Pending JP2016000750A (ja) 2010-01-25 2015-08-21 芳香族カチオン性ペプチドおよびその使用

Country Status (8)

Country Link
US (6) US20120329730A1 (enExample)
EP (4) EP3018138A1 (enExample)
JP (2) JP2013518057A (enExample)
CN (2) CN102834408A (enExample)
AU (2) AU2011207432A1 (enExample)
CA (2) CA3008993A1 (enExample)
HK (1) HK1208686A1 (enExample)
WO (1) WO2011091357A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017052742A (ja) * 2015-09-11 2017-03-16 キユーピー株式会社 抗酸化剤

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025734A1 (en) * 2009-08-24 2011-03-03 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
EP3511012A1 (en) * 2010-02-26 2019-07-17 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP2547352A4 (en) 2010-03-15 2013-10-09 Stealth Peptides Int Inc COMBINATION THERAPIES USING CYCLOSPORINE AND AROMATIC CATIONIC PEPTIDES
EP3290433A1 (en) * 2010-05-03 2018-03-07 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN102327600A (zh) * 2011-09-14 2012-01-25 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防和治疗辐射损伤的rx31肽
WO2013049697A1 (en) 2011-09-29 2013-04-04 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
EP3466439A1 (en) 2011-12-09 2019-04-10 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
JP6317324B2 (ja) * 2012-03-30 2018-04-25 ステルス ペプチドズ インターナショナル インコーポレイテッド 神経障害を予防および処置するための方法および組成物
CA2870200A1 (en) * 2012-04-12 2013-10-17 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
KR102236829B1 (ko) 2013-03-15 2021-04-07 프로타고니스트 테라퓨틱스, 인코포레이티드 헵시딘 유사체 및 이의 용도
US20140294902A1 (en) * 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide antagonists
CA2916492A1 (en) * 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
US20160175379A1 (en) * 2013-08-12 2016-06-23 Stealth Bio Therapeutics Corp Combination therapy for the treatment of ischemia-reperfusion injury
JP2016540762A (ja) * 2013-12-02 2016-12-28 ステルス バイオセラピューティックス コープ 白斑の治療のための組成物及び方法
AU2015258863B2 (en) 2014-05-16 2019-10-24 Protagonist Therapeutics, Inc. Alpha4beta7 integrin thioether peptide antagonists
AU2015289642B2 (en) 2014-07-17 2021-02-25 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2016054411A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
EP3265109B1 (en) 2015-03-06 2020-10-21 Stealth BioTherapeutics Corp Processes for preparing pharmaceutically relevant peptides
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2017093897A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2017117381A1 (en) * 2015-12-31 2017-07-06 Scott Duncan Therapeutic compositions including peptides and uses thereof
JP7038675B2 (ja) 2016-03-11 2022-03-18 ステルス バイオセラピューティクス インコーポレイテッド 結晶塩形態
WO2017180535A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
US10278957B2 (en) 2017-09-11 2019-05-07 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
EP3749345A4 (en) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS
TW202019948A (zh) 2018-07-12 2020-06-01 美商領導醫療有限公司 介白素-23受體之肽抑制劑及其治療發炎疾病之用途
AU2019401254B2 (en) * 2018-12-18 2025-05-01 Stealth Biotherapeutics Inc. Analogs that target mitochondrial diseases
MX2022000397A (es) 2019-07-10 2022-04-25 Protagonist Therapeutics Inc Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
KR20220141808A (ko) 2020-01-15 2022-10-20 얀센 바이오테크 인코포레이티드 인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도
CN118063554A (zh) 2020-01-15 2024-05-24 詹森生物科技公司 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
KR20230110570A (ko) 2020-11-20 2023-07-24 얀센 파마슈티카 엔.브이. 인터류킨-23 수용체의 펩티드 억제제의 조성물
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
TW202330013A (zh) 2021-07-14 2023-08-01 美商健生生物科技公司 介白素－２３受體之脂化肽抑制劑

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63264497A (ja) * 1987-01-02 1988-11-01 メルク　エンド　カムパニー　インコーポレーテッド ヒスチジン置換基を含むレニン阻害物質
JPH04502629A (ja) * 1989-11-06 1992-05-14 フアルミタリア・カルロ・エルバ・エツセ・エルレ・エルレ 還元不可逆性ボンベシンアンタゴニスト
JPH06509075A (ja) * 1991-07-01 1994-10-13 ユニヴァーシティ　テクノロジーズ　インターナショナル　インコーポレイテッド ＧｎＲＨ及び他の生物学的に活性なリガンドの非感度低下性類縁体
JP2006516652A (ja) * 2003-02-04 2006-07-06 コーネル リサーチ ファウンデイション インコーポレイテッド ミトコンドリア透過性転移の阻止方法
JP2007518818A (ja) * 2004-01-23 2007-07-12 コーネル リサーチ ファウンデイション インコーポレイテッド 酸化的損傷を低減する方法
WO2009100363A2 (en) * 2008-02-07 2009-08-13 Cornell University Methods for preventing or treating insulin resistance
WO2009108695A2 (en) * 2008-02-26 2009-09-03 Cornell University Methods for prevention and treatment of acute renal injury

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63264497A (ja) * 1987-01-02 1988-11-01 メルク　エンド　カムパニー　インコーポレーテッド ヒスチジン置換基を含むレニン阻害物質
JPH04502629A (ja) * 1989-11-06 1992-05-14 フアルミタリア・カルロ・エルバ・エツセ・エルレ・エルレ 還元不可逆性ボンベシンアンタゴニスト
JPH06509075A (ja) * 1991-07-01 1994-10-13 ユニヴァーシティ　テクノロジーズ　インターナショナル　インコーポレイテッド ＧｎＲＨ及び他の生物学的に活性なリガンドの非感度低下性類縁体
JP2006516652A (ja) * 2003-02-04 2006-07-06 コーネル リサーチ ファウンデイション インコーポレイテッド ミトコンドリア透過性転移の阻止方法
JP2007518818A (ja) * 2004-01-23 2007-07-12 コーネル リサーチ ファウンデイション インコーポレイテッド 酸化的損傷を低減する方法
WO2009100363A2 (en) * 2008-02-07 2009-08-13 Cornell University Methods for preventing or treating insulin resistance
WO2009108695A2 (en) * 2008-02-26 2009-09-03 Cornell University Methods for prevention and treatment of acute renal injury

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017052742A (ja) * 2015-09-11 2017-03-16 キユーピー株式会社 抗酸化剤

Also Published As

Publication number Publication date
AU2011207432A1 (en) 2012-08-02
WO2011091357A1 (en) 2011-07-28
EP2528934A4 (en) 2013-08-21
CA3008993A1 (en) 2011-07-28
US20190330272A1 (en) 2019-10-31
US20170008925A1 (en) 2017-01-12
CN104725472A (zh) 2015-06-24
US20130316964A1 (en) 2013-11-28
CA2787331A1 (en) 2011-07-28
CN102834408A (zh) 2012-12-19
US20180244721A1 (en) 2018-08-30
US20120329730A1 (en) 2012-12-27
EP2848628A1 (en) 2015-03-18
EP3018138A1 (en) 2016-05-11
AU2016200747A1 (en) 2016-02-25
US20150005242A1 (en) 2015-01-01
EP2733150A1 (en) 2014-05-21
HK1208686A1 (en) 2016-03-11
EP2528934A1 (en) 2012-12-05
JP2016000750A (ja) 2016-01-07

Similar Documents

Publication Publication Date Title
US20190330272A1 (en) Aromatic-cationic peptides and uses of same
US20210261613A1 (en) Aromatic-cationic peptides and uses of same
CN116440247A (zh) 治疗线粒体疾病的方法
EP3049096B1 (en) Use of aromatic-cationic peptides to treat niemann-pick disease characterised by cholesterol-induced mitochondrial dysfunction
CN115990242A (zh) 预防或治疗巴斯综合征的方法和组合物
AU2017261638A1 (en) Aromatic-cationic peptides and uses of same
HK1179977A (en) Aromatic-cationic peptides and uses of same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150522

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151202